CG Oncology Inc. CGON 深 沪
等待开盘 09-19 09:30:00 美东时间
38.80
+1.080
+2.86%
华盛通- 最 高39.15
- 今 开38.30
- 成交量 64.95万股
- 最 低 38.185
- 昨 收 37.72
- 总市值 29.58亿
- 52周最高 40.47
- 市盈率 静 --
- 换手率 0.85%
- 52周最低 14.80
- 委 比 73.58%
- 总股本 7622.53万
- 历史最高 50.23
- 量 比 0.44
- 振 幅 2.56%
- 历史最低 14.80
- 每 手 1
- 风险率 4.95%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Tigress Financial：维持苹果"强烈买入"评级，目标价升至305美元；杰富瑞维持百度"买入"评级，目标价升至157美元
今日重点评级关注：HC Wainwright & Co.：维持Astria Therapeutics"买入"评级，目标价从16美元升至20美元；HC Wainwright & Co.：维持Avalo Therapeutics"买入"评级，目标价从15美元升至25美元
09-18 10:13
Morgan Stanley Maintains Overweight on CG Oncology, Raises Price Target to $79
Morgan Stanley analyst Jeffrey Hung maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $56 to $79.
09-18 02:00
美股大行评级 | Bernstein：首予Bullish"与大市齐平"评级，目标价60美元
今日重点评级关注：TD Cowen：上调加拿大鹅评级至"买入"，目标价从16美元升至18美元；Vertical Research：上调波音评级至"买入"，目标价从242美元升至270美元
09-09 09:58
CG Oncology Stock Signals Bullish Momentum Ahead
CG Oncology has entered its Phase 2 of the Adhishthana Cycle, signaling a bullish setup. With momentum already building, here's what to track...
09-08 21:08
美股大行评级 | 潜在涨幅65.5%！花旗上调Braze目标价至52美元，维持"买入"评级
今日重点评级关注：花旗：维持Braze"买入"评级，目标价从50美元升至52美元；花旗：维持Docusign"买入"评级，目标价从115美元升至120美元
09-08 10:23
CG Oncology Announced Updated Data On BOND-003 Cohort C Showing 12 Additional Patients With High Risk Non-muscle Invasive Bladder Cancer Were In Complete Response At 24 Months, With Complete Response Rate Of 41.8%
Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG)
09-05 19:04
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
CG Oncology announced updated data from its Phase 3 BOND-003 Cohort C study, showing cretostimogene monotherapy achieved a 24-month complete response rate of 41.8% in high-risk non-muscle invasive bladder cancer (NMIBC) patients unresponsive to BCG. The study also revealed that 90% of 12-month responders remained disease-free at 24 months with no Grade 3 or higher treatment-related adverse events. These results highlight cretostimogene's durabili...
09-05 11:00
CG Oncology Completes Enrollment in PIVOT-006
CG Oncology announces the completion of enrollment for its Phase 3 PIVOT-006 study evaluating cretostimogene in intermediate-risk non-muscle invasive bladder cancer (NMIBC). Over 360 patients were enrolled across 90+ sites, reflecting high unmet need in this patient population. The study investigates adjuvant therapy versus surveillance, with the potential to address up to 70% recurrence rates. The therapy combines tumor cell lysis and immune act...
09-03 12:00
CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences
CG Oncology executives Arthur Kuan and Ambaw Bellete are set to speak at the Cantor Global Healthcare Conference on September 5, 2025, and the Morgan Stanley Global Healthcare Conference on September 9, 2025. Both events will be held in New York, NY. Live webcasts and replays of the presentations will be available on the company's Investor Relations website at www.cgoncology.com.
08-29 12:00
Piper Sandler initiates coverage of oncology companies
Piper Sandler launched coverage for a few biotech companies in the oncology space, as mentioned below: CG Oncology (NASDAQ:CGON) rated Overweight with a $55 price target: "Investor expectations for cr...
08-19 23:17
